First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US

FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements

Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial

Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia

FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse

Cognetivity Neurosciences Releases Latest Version of AI-powered Brain Health Assessment Platform

Awakn Life Sciences Announces the Opening of Its Fourth Clinic

Filament Health Announces Second Psilocybin Supply Agreement With The Centre For Addiction And Mental Health

Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv

IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

Awakn Life Sciences Initiates Feasibility Study for MDMA Using Catalent's Zydis Orally Disintegrating Tablet (ODT) Technology

Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity